Tempus AI shares jumped more than 10% after management gave investors a clearer view of the company’s longer-term growth trajectory, arguing that annual expansion of at least 25% could be sustained for years. The comments came as investors reassessed the durability of growth at the healthcare AI company, where diagnostics, proprietary data and artificial intelligence are increasingly converging into a broader business model.

Management Sees a Multi-Year 25% Growth Opportunity

CEO and founder Eric Lefkofsky said Tempus would rather operate a business that grows at 25% for a decade than one that expands at 35% for only a few years. The strategy reflects an emphasis on building a durable growth model rather than maximizing short-term expansion.

Tempus has already raised its 2026 revenue guidance to $1.595–$1.605 billion, representing approximately 25% annual growth. Management’s latest comments suggest the company sees a path to maintaining a similar growth rate beyond 2026 as new products, reimbursement improvements and data-related opportunities expand the addressable market.

Diagnostics and Data Provide Two Major Growth Engines

Tempus reported second-quarter revenue of $382.5 million, up 22% from a year earlier. Diagnostics generated $289.3 million, representing 20% year-over-year growth, while oncology test volumes increased 31%. Molecular residual disease testing also grew, reaching 9,000 tests during the quarter compared with 6,500 in the previous quarter.

The data business is expanding even faster. Data and Applications revenue increased 28% year over year to $93.2 million, while Insights revenue rose 36%. Tempus also signed approximately $200 million in new Data and Applications licenses, reinforcing the role of its proprietary clinical and genomic datasets in the company’s growth strategy.

Reimbursement and AI Could Extend the Growth Runway

One of management’s key arguments is that revenue growth can come not only from higher test volumes but also from improved pricing. Tempus said its FDA approval for the tumor-only version of its xT assay should allow the company to migrate the platform to ADLT pricing, potentially adding approximately $80 million to $100 million in annual revenue. Its liquid-biopsy product is also being reviewed by the FDA.

The company is simultaneously expanding its AI capabilities. Tempus delivered its first oncology foundation model to AstraZeneca and continues developing AI-enabled healthcare products that use its large multimodal data library. It has also agreed to acquire Personalis, a transaction expected to further expand its molecular residual disease capabilities.

The key test for TEM will be whether the company can sustain approximately 25% growth as its revenue base becomes larger while improving profitability. Tempus posted $5.6 million of GAAP net income and $8.0 million of Adjusted EBITDA in the second quarter, and expects approximately $65 million of Adjusted EBITDA for full-year 2026. Investors will be